immunogenic peptide Search Results


bf33 peptide  (ImmunoGen Inc)
90
ImmunoGen Inc bf33 peptide
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
Bf33 Peptide, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/bf33+peptide/pmc03360004-167-32-28
Average 90 stars, based on 1 article reviews
bf33 peptide - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
klh-conjugated hiv peptide  (ImmunoGen Inc)
90
ImmunoGen Inc klh-conjugated hiv peptide
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
Klh Conjugated Hiv Peptide, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/klh+conjugated+hiv+peptide/pm40005649-569-16-7
Average 90 stars, based on 1 article reviews
klh-conjugated hiv peptide - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
il-6 b cell epitope peptide c73-c83  (ImmunoGen Inc)
90
ImmunoGen Inc il-6 b cell epitope peptide c73-c83
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
Il 6 B Cell Epitope Peptide C73 C83, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/il+6+b+cell+epitope+peptide+c73+c83/us12350322-624-10-41
Average 90 stars, based on 1 article reviews
il-6 b cell epitope peptide c73-c83 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
15-169 mer clade b consensus v3 peptide v3conb  (ImmunoGen Inc)
90
ImmunoGen Inc 15-169 mer clade b consensus v3 peptide v3conb
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
15 169 Mer Clade B Consensus V3 Peptide V3conb, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/15+169+mer+clade+b+consensus+v3+peptide+v3conb/10__1128_slash_jvi__01894___17-64-6-21
Average 90 stars, based on 1 article reviews
15-169 mer clade b consensus v3 peptide v3conb - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
peptide immunogen containing residues 200–250 of mepce  (ImmunoGen Inc)
90
ImmunoGen Inc peptide immunogen containing residues 200–250 of mepce
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
Peptide Immunogen Containing Residues 200–250 Of Mepce, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/peptide+immunogen+containing+residues+200+250+of+mepce/10__7554_slash_elife__53930-106-17-12
Average 90 stars, based on 1 article reviews
peptide immunogen containing residues 200–250 of mepce - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
irrelevant peptide  (ImmunoGen Inc)
90
ImmunoGen Inc irrelevant peptide
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
Irrelevant Peptide, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/irrelevant+peptide/pmc03637173-179-38-16
Average 90 stars, based on 1 article reviews
irrelevant peptide - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cytokine peptides  (ImmunoGenes)
90
ImmunoGenes cytokine peptides
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
Cytokine Peptides, supplied by ImmunoGenes, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/cytokine+peptides/us07892529-92-28-35
Average 90 stars, based on 1 article reviews
cytokine peptides - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
il-6 peptide immunogen constructs  (ImmunoGen Inc)
90
ImmunoGen Inc il-6 peptide immunogen constructs
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
Il 6 Peptide Immunogen Constructs, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/il+6+peptide+immunogen+constructs/us12350322-680-6-8
Average 90 stars, based on 1 article reviews
il-6 peptide immunogen constructs - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
peptide pools of two main immunogenic cmv antigens ie-1 and pp65  (Immunotec inc)
90
Immunotec inc peptide pools of two main immunogenic cmv antigens ie-1 and pp65
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
Peptide Pools Of Two Main Immunogenic Cmv Antigens Ie 1 And Pp65, supplied by Immunotec inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/peptide+pools+of+two+main+immunogenic+cmv+antigens+ie+1+and+pp65/pm38727765-64-29-42
Average 90 stars, based on 1 article reviews
peptide pools of two main immunogenic cmv antigens ie-1 and pp65 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
boost#2 immunogen fusion peptide  (ImmunoGen Inc)
90
ImmunoGen Inc boost#2 immunogen fusion peptide
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
Boost#2 Immunogen Fusion Peptide, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/boost+2+immunogen+fusion+peptide/pm38997302-99-12-13
Average 90 stars, based on 1 article reviews
boost#2 immunogen fusion peptide - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
peptide immunogens  (AnaSpec)
90
AnaSpec peptide immunogens
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
Peptide Immunogens, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/peptide+immunogens/pm16365462-51-1-13
Average 90 stars, based on 1 article reviews
peptide immunogens - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
synthetic peptide immunogen  (ImmunoGen Inc)
90
ImmunoGen Inc synthetic peptide immunogen
A ) Functional avidity of the BF33- and <t>B84-specific</t> T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.
Synthetic Peptide Immunogen, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunogenic+peptide/synthetic+peptide+immunogen/10__1128_slash_mcb__7__5__1585-148-31-33
Average 90 stars, based on 1 article reviews
synthetic peptide immunogen - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


A ) Functional avidity of the BF33- and B84-specific T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.

Journal: PLoS ONE

Article Title: IL-12 and GM-CSF in DNA/MVA Immunizations against HIV-1 CRF12_BF Nef Induced T-Cell Responses With an Enhanced Magnitude, Breadth and Quality

doi: 10.1371/journal.pone.0037801

Figure Lengend Snippet: A ) Functional avidity of the BF33- and B84-specific T-cells: Groups of 4 mice received the immunization schemes depicted in for the group 1 (NefBF alone) and group 2 (plus IL-12 during the priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides. Peptide concentrations used ranged from 20 to 0.002 µg/ml. SD 50 : sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-γ production. B ) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc, were subtracted in each case. T test was applied, *p<0.05, * * p<0.005.

Article Snippet: In these experiments, the responses found in the control vs the IL-12 group were compared, analyzing the avidity of the T-cells against the BF33 (same sequence as the immunogen vectors) or the B84 peptide (with 3 aa changes, see ), in order to define if the recognition pattern differed between homologous or heterologous responses.

Techniques: Functional Assay, Staining

<xref ref-type= Results summary." width="100%" height="100%">

Journal: PLoS ONE

Article Title: IL-12 and GM-CSF in DNA/MVA Immunizations against HIV-1 CRF12_BF Nef Induced T-Cell Responses With an Enhanced Magnitude, Breadth and Quality

doi: 10.1371/journal.pone.0037801

Figure Lengend Snippet: Results summary.

Article Snippet: In these experiments, the responses found in the control vs the IL-12 group were compared, analyzing the avidity of the T-cells against the BF33 (same sequence as the immunogen vectors) or the B84 peptide (with 3 aa changes, see ), in order to define if the recognition pattern differed between homologous or heterologous responses.

Techniques: Control